This breaking news should vastly improve awareness of Coriolus Versicolor across the US which can only be a good thing!

Original post by http://blog.amlaspain.com

Share on Facebook

Testimony about treatments and alternate therapy using Coriolus Versicolor abound. Here is one such relating to lung cancer In private practice for 15 years, Dr. Bailey has taught courses in nutrition and pharmacognosy at the National College of Naturopathic Medicine in Portland. He has been using the Coriolus versicolor polysaccharide extract for three years to relieve such illnesses as hepatitis B and C, AIDS, herpes genitalis, cancer, general immune suppression, and post-surgical recovery. Usually Dr. Bailey doesn’t administer the Coriolus polysaccharides as a single treatment agent; rather, it becomes part of his fairly comprehensive nutritional protocol. “Of course, some cancer patients take Coriolus versicolor even while they engage in radiation treatment or chemotherapy” Dr. Bailey advises. “Or, the patients don’t submit to chemotherapy or radiotherapy at all but rely, instead, exclusively on nutritional therapies with the mushroom as a main treatment ingredient. For example, one of my patients, a 34 year-old woman working in the health field consulted me with a cancer spreading at two sites in her lungs. Orthodox treatment had been tried but no longer was effective. She embarked on nutritional therapies and completed six months of taking Coriolus versicolor. Radiological examination then showed that all of her lung tumors had disappeared. Seeing her current progress, orthodox medicine probably would declare this patient to be cured.” (Extract from “ the Medicinal Mushroom - womenshealth-naturalsolutions.com) Share on Facebook

If you haven’t heard of Coriolus Versicolor then do not worry because not many people have. Just Google it and see what it does. then you may start to realise that you are reading about the chance to change your financial future.

Coriolus isnt just big….its a game changer, life changer….what ever you want to call it. And you have the chance to get in on the ground floor of a business that is set to change lives.

inForce by inLife LLC is a propietary extraction of Coriolus Versicolor PSK & PSP. its immune system boosting qualities are out there in the 400+ independent studies, clinical trials and articles. its ant cancer properties and anti tumour effects can be read and studied.

inForce is set to change your families health and if you want to get paid for telling the people around you about this incredible mushroom then you have a chance to get involved in the biggest network marketing explosion the industry has ever seen.

This is probably one of the first posts ever written about the opportunity for Network marketing and Coriolus Versicolor.

So go away and do the research and also click on the link to view information about inLife and its other products.

View information about inForce by inLife – Click here

Go to Google search

Share

Numerous clinical trials have been carried out over the years with PSK derived from Trametes versicolor (Coriolus versicolor, Poyporous Versicolor, Turkey tail, Yun Zhi) and are briefly summarised below:

PSK:

There have been several decades of successful clinical trials using PSK to treat head and neck, upper GI, colo-rectal and lung cancers with some reported success in treating breast cancer as well.  Clinical trials with PSK have recently been extensively reviewed by Kidd (2000) and will be briefly summarised here.  Almost exclusively, clinical trials have been carried out in Japan.

PSK and gastric cancer:

PSK has been used as a form of immunotherapy for more gastric cancer patients than any other cancer type.  In early 1970s Kaibara’s group began trialing PSK with their existing chemotherapy regimens for stage IV disease (Kaibara et al., 1976).  After surgical resection (partial or full gastrectomies), PSK at 3g per day was added to a chemotherapy regimen of Mitomycin C and 5-fluorouracil (5-FU) (n=66). When compared with a historical control group, the 2 year survival rate was more than double, a finding that was later confirmed by Fujimoto et al. (1979) in a larger prospective study (n= 230).  Further studies by Hattori et al. (1979) (n=110) and Kodama et al. (1982) (n =450) suggested that PSK gave some protection against the immunosuppression that normally is associated with surgery and long-term chemotherapy.

One of the few double-blind randomised controlled trials (n=144) examining the role of single agent PSK found a significant increase in disease-free and overall survival.  PSK had significant effects on these patients immune systems as measured by increased delayed-type hypersensitivity on skin tests and enhanced chemotactic migration of neutrophils (Kondo and Torisu, 1985). All these studies suggest that individuals with very low immunity are less likely to benefit from PSK therapy than individuals with a reasonably competent immune system.  Other non- randomised trials in Japan have supported these findings (Mitomi and Ogoshi, 1986; Niimoto et al., 1988; Maehara et al., 1990; Nakazato et al., 1994).  Tsujitani et al. (1992) had previously observed that dendritic cells could infiltrate gastric cancers in some patients and biopsy examination correlated this dendritic infiltration of their tumours with an increase in disease-free and overall survival post-surgery.  It was concluded that patients with gastric cancer with limited dendritic cell infiltration prior to surgery when given PSK immunotherapy were more likely to have significant response.  The most recent phase III 2 arm trial of PSK in the treatment of gastric cancer carried out by the “Study Group of Immunochemotherapy with PSK for Gastric Cancer of Japan” showed that combining PSK with conventional chemotherapy significantly improved disease-free and overall survival (Nakazato et al., 1994).

PSK and other cancers

In a non-controlled, retrospective analysis of combined radiation, chemotherapy and immunotherapy (using PSK or OK-32, another immuno- potentiator) with 133 patients with oesophageal cancer, there were improvements in one-year and two-year survival (Okudaira et al., 1982).  In another more recent study PSK improved overall survival in oesophageal cancer in patients with levels of pre-operative high α1-anti-chymotrypsin or sialic acid (Ogoshi et al., 1995).  In a small scale trial in Taiwan for nasopharngeal carcinoma PSK adjunct therapy had a small but significant impact on five-year survival (Go and Chung, 1989).

In a study of 185 patients with epidermoid carcinoma, adenocarcinoma or large-cell carcinoma (≤ IIIb) given PSK as an immune system potentiator following radiotherapy, almost four times more patients who were treated with PSK had significant improvements in disease-free survival than those not given PSK (Hayakawa et al., 1993).  PSK was clinically significant with more advanced patients with Stage III disease than Stage I and II patients.  PSK had greater activity for older patients (> 70 years) and patients with small primary tumours. Early studies with breast cancer patients seemed to imply that long-term PSK immunotherapy in conjunction with chemotherapy could have beneficial results (Suginachi et al., 1984).  In a later much larger trial (914 patients) in-depth analysis implied that PSK significantly extended survival in ER-negative, Stage IIA patientswithout lymph node involvement (Toi et al., 1992).  However, in a further large trial, Morimoto et al. (1996) could find no statistical evidence of any benefit from PSK.

These contradictory studies may have been clarified by Yokoe et al. (1997) who compared HLA B40 antigen positive patients treated with PSK against B40 negatives.  It was found that B40-positive patients treated with PSK (3g/daily, two month course each year) in addition to chemotherapy had an improved 10 year overall survival rate compared to B-40 negative patients.  Thus, HLA B40 may be a predictive factor for PSK response.

The foregoing studies give strong indications of the potential benefits of incorporating PSK into some cancer treatments as an adjunct to radio- or chemotherapy.  Furthermore, PSK can improve immune status secondary to the side effects associated with traditional therapies.  As stated by Kidd (2000)  “after a quarter century of trials indicating PSK can improve cancer survival, the cumulative human findings amount to a recommendation for its inclusion in standard anticancer protocols. With its risk for adverse effects virtually nonexistent, PSK’s contribution to the benefit-risk profiles of these protocols can only be positive”.

Extracts taken from: THE ROLE OF POLYSACCHARIDES DERIVED FROM MEDICINAL MUSHROOMS IN CANCER (icnet.uk)

Share on Facebook

PSP and clinical trials

While PSK has been almost exclusively developed and tested within Japan, PSP in contrast is a product of China and continues to be assessed for efficacy safety by their scientists and oncologists.  There is a close similarity between PSK and PSP polypeptides although PSP lacks fucose and instead contains arabinose and rhamnose.  Since the first development of PSP in 1983 there has been rapid progress through human clinical trials.  Phase I clinical trials were carried out by Xu (1993) and it was shown that an oral dose of up to 6g/day was well talented and lacking in side-effects.  Patients showed improvement in appetite and general condition, together with a stabilisation of haematopoietic parameters.

The Phase II study by the Shanghai PSP Research Group with 8 hospitals in Shanghai was carried out using patients with cancers of the stomach, lung and oesophagus. The dosage was 1g three times daily to a total of 190g.  Results confirmed the role of PSP as a biological response modifer improving the immunological status of the patients after surgery, radiotherapy and/or chemotherapy (Liu and Zhou, 1993).  Following the success of the Phase II clinical trials, a Phase III trial was conducted in a large cohort of patients (650) in Shanghai hospitals.  189 were randomised to taking PSP and placebo;  461 patients were unblinded to their therapy (Liu et al., 1999).  These trials showed that PSP improved disease-free survival of gastric, oesophageal and non-small-cell lung cancers while again substantially reducing the normal unpleasant side-effects of conventional treatments (Sun and Zhu, 1999; Sun et al., 1999).  PSP had a protective effect on the immunological functions of conventionally-treated patients, thus demonstrating that PSP can be classified as a clinical biological response modifier.  Other BRMs such as LAK cells, IL-2, α y IFN or TNF are also being used in the treatment of advanced cancer cases (Liu, 1999).  Yet, these drugs at effective doses, in many cases, produce quite severe side-effects such as fevers, chills, rashes, arthralgia, hypotension, oliguria, pulmonary oedema, congestive heart failure and CNS toxicities.  Mao et al. (1998) have shown dramatic anti-tumour effects when PSP was combined with IL-2.  As side-effects of IL-2 are dosage and schedule dependent, it isreasonable to expect that with PSP, a lower dose of IL-2 could be used clinically withsubsequent decrease in the severity of the side-effects (McCune and Chang, 1993).

A further observation noted that PSP in combination with radiotherapy induced a significant increase in the percentage of apoptotic cells at 24h, compared with radiation alone, and it has been surmised that the antitumour mechanism of PSPaction may also involve the induction of DNA damage by apoptosis in the target cancer cells (Stephens et al., 1991). A common adverse reaction of radiotherapy and chemotherapy is haematopoietic toxicity.  Several studies have shown a strong amelioration of thesetoxic effects by PSP (Shiu et al., 1992; Sun et al., 1999).

In a double-blind Phase II trial in Shanghai hospitals almost 300 patients suffering from gastric, oesophageal or lung cancer  were treated with conventional radiotherapy and/or chemotherapy together with PSP or shark liver oil (batyl alcohol).  Quality of life was assessed by marked improvement of clinical symptoms as well as improvements in blood profiles and/or immune indices and significant improvement in Karnovsky performance status or body weight.   PSP improved overall clinical symptoms, together with most symptoms associated with cancer therapy.  PSP was found to be effective for 82% of the patients compared with 48%for batyl alcohol (Liu and Zhou, 1993).

Many Phase III clinical trials of PSP combined with conventional therapies have demonstrated significant benefits against cancers of the stomach, oesophagus and lung (Jong and Yang, 1999; Yang, 1999).  Most studies with PSP have not fullyexplored the long-term survival benefit although in an open-label, randomised trial in oesophageal cancer has shown that PSP did significantly improve one-year and three-year survival (Yao, 1999).  Liu (1999) has commented on the favourable action of PSP in patients receiving bone autologous marrow transplants.

The corpus of laboratory and clinical evidence that PSP offers considerable benefits to patients suffering from cancers of the stomach, oesophagus and lung have led to the Chinese Ministry of Public Health granting it a regulatory license.

Extracts taken from: THE ROLE OF POLYSACCHARIDES DERIVED FROM MEDICINAL MUSHROOMS IN CANCER (icnet.uk)

Share on Facebook